CN | EN

Countdown to 2018 CBIIC:

YANG Dajun

Chairman & CEO of Ascentage Pharma


Dr. Yang, M.D., PH.D., the expert of “National Thousand Talents Plan”, is the Chairman & CEO of Ascentage Pharma. He has nearly 30 years of experience in targeted anti-cancer drug research and translating the research ideas into clinical development stage products. Dr. Yang co-founded Ascentage Pharma in 2009, and has established a China-based R&D team with international standards with seven targeted oncology therapeutic NCE compounds in phase I and phase II trials in US, Australia and China. Before Ascentage Pharma, Dr. Yang co-founded US Ascenta Therapeutics in 2003, where he was Senior VP of Research and preclinical development. Previously, Dr. Yang was associate professor of internal medicine and member of the Comprehensive Cancer Center at the University of Michigan; and associate professor in the department of oncology and a senior investigator of the Lombardi Cancer Center at the Georgetown University Medical Center. He has accumulated nearly $10 million in research grants from NIH, cancer foundation and NCI RAID. He is the author or co-author of 92 publications and the inventor of 14 patents. Dr. Yang also serves as part-time professor and Ph.D. supervisor at the Sun Yat-sen University Cancer Center, industry professor of China Pharmaceutical University, and vice chairman of R&D committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA).